Waltham, MassThe FDA has granted Oxigene's combretastatin A4P (CA4P) orphan drug status for treatment of ovarian cancer. In a phase Ib trial, advanced ovarian cancer patients who had failed previous therapy showed a 67% response rate to CA4P plus carboplatin(Drug information on carboplatin) and paclitaxel(Drug information on paclitaxel), the company said in a news release. This combination is currently being evaluated in a phase II trial in women with platinum-resistant ovarian cancer.
